. G-banded karyotype showing two hsr regions (long arrows), t(14;16)(q32;q23) (short arrows) as well as other abnormalities.
Relapse: Her disease recurred and spread to extramedullary sites spleen and lymph nodes; expired 5 months after diagnosis. (Figure 1 ).
Status: Death

Other Molecular Studies
Technics:
Fluorescence in situ hybridization using LSI D13S319/LAMP, TP53 and IGH/MAF DNA probes (Abbott Molecular) revealed loss of chromosome 13, deletion of p53 and IGH-MAF/t(14;16) in approximately 60% of interphase cells.
Results:
Furthermore, hybridization with LSI IGH/CMYC/CEP-8 probe set showed that the two copies of hsr were entirely labeled with CMYC ( Figure 2B ).
Comments
We report a case of primary PCL admitted to the hospital due to severe diarrhea and a history of 2 months of bone pain. She was found to havehypercalcemia, and at that time her peripheral blood showed 40% abnormal plasma cells. Cytogenetic analysis revealed a hypodiploid karyotype with complex abnormalities including monosomy 13, deletion 17p/p53, t(14;16)/IGH-MAF and two copies of hsr indicating a high risk disease (Figure 1 ). Metaphase FISH revealed that the hsr were positive for CMYC sequences ( Figure 2B ). In leukemia, double minute (dmin) and hsr are signs of gene amplification, most often represent the CMYC oncogene or drug resistance genes. Dmins tend to occur in elderly with a myelodysplastic syndrome and acute myeloid leukemia, and are associated with a rapid and aggressive clinical outcome. However, an hsr is extremely rare in leukemia and based on our search in the medical literature, the present case is the first report of CMYC amplification in the form of an hsr seen in myeloma. In contrast, development of PCL in this patient at relatively young age is quite uncommon, possibly due to history of exposure to mutagens which initiate a series of DNA mutations. The presence of an hsr in this case is also associated with a very bizarre plasma cell morphology and dismal clinical course. As seen in our patient, dmin and hsr have been described in association with deletion of 17p13/p53, suggesting that loss of p53 primes leukemic cells by increasing their survival, therefore allowing deregulation of other oncogenes such as CMYC and RAS. Still the molecular events that allow the plasma cells to escape the bone marrow environment are unclear. Sequential involvement and cooperation of multiple oncogenes and tumor suppressor genes, as well as other epigenetic events, are required for plasma cell expansion into the peripheral blood and extramedullary tissues.
